Targeting of an A Kinase-anchoring Protein, AKAP79, to an Inwardly Rectifying Potassium Channel, Kir2.1*

Caroline DartDagger § and Mark L. Leyland

From the Departments of Dagger  Cell Physiology & Pharmacology and  Biochemistry, University of Leicester, P. O. Box 138, Leicester LE1 9HN, United Kingdom

Received for publication, February 14, 2001, and in revised form, March 23, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Protein kinase A (PKA) is targeted to discrete subcellular locations close to its intended substrates through interaction with A kinase-anchoring proteins (AKAPs). Ion channels represent a diverse and important group of kinase substrates, and it has been shown that membrane targeting of PKA through association with AKAPs facilitates PKA-mediated phosphorylation and regulation of several classes of ion channel. Here, we investigate the effect of AKAP79, a membrane-associated multivalent-anchoring protein, upon the function and modulation of the strong inwardly rectifying potassium channel, Kir2.1. Functionally, the presence of AKAP79 enhanced the response of Kir2.1 to elevated intracellular cAMP, suggesting a requirement for a pool of PKA anchored close to the channel. Antibodies directed against a hemagglutinin epitope tag on Kir2.1 coimmunoprecipitated AKAP79, indicating that the two proteins exist together in a complex within intact cells. In support of this, glutathione S-transferase fusion proteins of both the intracellular N and C domains of Kir2.1 isolated AKAP79 from cell lysates, while glutathione S-transferase alone failed to interact with AKAP79. Together, these findings suggest that AKAP79 associates directly with the Kir2.1 ion channel and may serve to anchor kinase enzymes in close proximity to key channel phosphorylation sites.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The phosphorylation state of ion channels is governed by the activation of protein kinases and phosphatases, which in turn respond to fluctuations in the local concentration of second messengers such as calcium and cyclic AMP. It has been shown recently that much of the specificity seen in intracellular phosphorylation events comes from the targeting of protein kinases and phosphatases to specific subcellular structures and organelles through association with anchoring or adaptor proteins (1, 2). Cyclic AMP-dependent protein kinase (protein kinase A or PKA),1 for example, is targeted to discrete subcellular locations through interaction with A kinase-anchoring proteins or AKAPs (3, 4). AKAPs form a family of more than thirty different functionally related proteins. Each anchoring protein contains at least two functional motifs: an amphipathic helix that binds the regulatory (RII) subunits of the PKA holoenzyme (5, 6) and a specialized anchoring domain that tethers the AKAP·PKA complex to specific intracellular sites close to their intended substrate (7). The modulation of ion channel activity through protein phosphorylation is an important physiological control mechanism, and ion channels represent a diverse group of kinase substrates. It has been shown that membrane targeting of PKA through association with AKAPs facilitates PKA-mediated phosphorylation and regulation of AMPA-kainate and NMDA glutamate ion channels, skeletal and cardiac calcium channels, and calcium-activated potassium channels (8, 9, 10, 11). Interestingly, AKAP15/18, the anchoring protein that targets PKA to L-type calcium channels does so not only by membrane association through a lipid anchor but also by a possible direct interaction with Ca2+ channel alpha  subunits (12, 13).

Inwardly rectifying potassium (Kir) channels are another group of ion channels whose modulation is influenced by the presence of AKAPs (14). Intrinsic gating and block of the Kir channel pore by intracellular magnesium and polyamines ensures that Kir channels permit K+ entry under hyperpolarization more readily that they permit K+ exit under depolarization (15, 16). This asymmetry in the current-voltage relation of the channel allows modification of the electrical properties of cells without excessive K+ loss. Consequently, Kir channels are involved in setting and maintaining the resting membrane potential, buffering extracellular K+, and the generation of prolonged action potentials in the heart and in fertilized egg cells (17). Kir channels are also regulated by protein phosphorylation and direct G-protein activation and thus play a role in the fine-tuning of cellular excitability (18, 19, 20). Cloning of members of the Kir family and examination of their primary sequences suggest the presence of multiple consensus phosphorylation sites (21, 22, 23), although experimental data for the involvement of kinase enzymes in the regulation of cloned Kir channel activity are contradictory, with evidence in favor as well as against a role for protein kinase A and/or protein kinase C (24, 25, 26).

Here, we present evidence that suggests that AKAP79 (recently renamed AKAP5),2 a multivalent-anchoring protein that binds PKA, PKC, and the protein phosphatase calcineurin (PP2B) (27, 28), is not only required for the reliable modulation of the strong inward rectifying K+ channel, Kir2.1, but further that AKAP79 is targeted to the intracellular N and C domains of Kir2.1 to anchor kinases close to key channel phosphorylation sites.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Antibodies, Polyacrylamide Gel Electrophoresis, and Immunoblotting-- The following primary antibodies were used: rabbit polyclonal HA-probe (Y-11; Santa Cruz Biotechnologies, Inc.); mouse monoclonal anti-AKAP79 (clone 22; BD Transduction Laboratories). Horseradish peroxidase-, fluorescein (FITC)- and Texas Red-conjugated anti-rabbit and anti-mouse secondary antibodies were from Jackson ImmunoResearch Laboratories, Inc. Protein extracts were resolved by SDS-polyacrylamide gel electrophoresis on 10% polyacrylamide-Tris gels and transferred electrophoretically onto nitrocellulose membranes (Hybond ECL, Amersham Pharmacia Biotech). Membranes were blocked overnight at 4 °C in blocking solution containing 5% (w/v) skim milk powder and 0.1% Tween 20 in Tris-buffered saline. Primary antibodies were diluted in blocking solution containing 1% skim milk powder and 0.1% Tween 20 in Tris-buffered saline and incubated with the membranes for 2-3 h at room temperature. Membranes were washed in Tris-buffered saline and then incubated with horseradish peroxidase-conjugated secondary antibodies for a further hour at room temperature. Labeled bands were visualized using enhanced chemiluminescence (ECL; Amersham Pharmacia Biotech) according to the manufacturer's protocol.

Cells and Cell Transfection-- Chinese hamster ovary (CHO), COS-7, and HEK-293 cells were grown in minimal essential medium (without nucleosides), Dulbecco's modified Eagle's medium, and minimal essential medium supplemented with 1% non-essential amino acids, respectively. Medium was supplemented with 10% (v/v) fetal bovine serum. All medium and reagents were from Life Technologies, Inc. No antibiotics were used. Cells were transiently transfected using FuGENE6TM transfection reagent (Roche Molecular Biochemicals) according to the manufacturer's protocol. Transfections were performed in six-well culture plates with cells at 50-80% confluence.

Plasmids and DNA Constructs-- The Kir2.1 expression construct in pcDNA3 has been previously described (29). The AKAP79 expression construct in pcDNA3 was a generous gift from Dr. John Scott, Vollum Institute, Portland, OR. The enhanced green fluorescent protein-Kir2.1 fusion (EGFP·Kir2.1) was produced as described previously (30). The expression vector encoding EGFP (pEGFP-N1) was purchased from CLONTECH. To confirm the presence of AKAP79 within cells during electrophysiological recordings, AKAP79 was subcloned as a SacI-BamHI fragment into the bicistronic expression vector pIRES2-EGFP (CLONTECH). This permits AKAP79 and EGFP to be translated simultaneously from the same mRNA transcript and allows visual selection of cells expressing both proteins.

For insertion of the HA epitope into the extracellular M1-H5 loop of Kir2.1, complimentary oligonucleotides encoding the HA epitope (YPYDVPDYA) were annealed to form a SphI adapter and ligated into a unique SphI site in Kir2.1 cDNA. The amino acid sequence of the HA-tagged Kir2.1 reads 117KVSKACYPYDVPDYAACV123 at the site of the epitope insertion. The HA·Kir2.1 construct was subcloned from the plasmid vector pBluescript into pcDNA3 as an EcoRI-XhoI fragment for transfection into COS-7 and HEK-293 cell lines.

Glutathione S-transferase (GST) fusion protein constructs encoding the N-terminal (1-71) and C-terminal (302) regions were amplified using the polymerase chain reaction with the following sets of primers: N-(1-71), 5'-GGATCCATGGGCAGTGTGAGAACCAACCGCTA-3' and 5'-GAATTCGTCTGCCAGGTACCTCTGTCCCTTCTC-3'; C-(302-428), 5'-GGATCCGAGGCGACTGCCATGACAACTCAATG-3' and 5'-GAATTCTCATATCTCCGATTCTCGCCTTAAGGG-3'.

Products of the reaction were cloned into the pGEM-T vector (Promega), digested with BamHI and EcoRI, and subcloned into the pGEX-2T bacterial expression plasmid (Amersham Pharmacia Biotech). The GST fusion protein construct C-(421-428) was constructed by annealing complimentary oligonucleotides encoding the C-terminal eight amino acids of Kir2.1 to form a BamHI-EcoRI adapter and ligating this into pGEX-2T.

GST Pull-down Assays-- To identify possible interactions between Kir2.1 and AKAP79, GST fusion proteins of the intracellular N (residues 1-71) and C (residues 302-428 and residues 421-428) domains of Kir2.1 were incubated with lysates of COS-7 cells expressing AKAP79. The expression plasmid pGEX-2T containing the GST fusion protein cDNA was transformed into Escherichia coli XL1 Blue competent cells (Stratagene). 15-ml overnight cultures were grown in Luria Bertani medium containing 100 µg/ml ampicillin (LBA). 200 µl of the overnight culture were then used to inoculate 4 × 12 ml of LBA. Cells were grown by shaking at 37 °C until the A600 was between 0.5 and 0.8. Expression of the GST fusion proteins was subsequently induced with 1 mM isopropyl-beta -D-thiogalactopyranoside and incubation was continued for a further 4-5 h. Cells were pelleted by centrifugation and resuspended in 500 µl of phosphate-buffered saline (PBS). Resuspended cells were lysed by mild sonication with a sonicator probe for 2 × 5 s on ice. 50 µl of 10% Triton X-100 was then added to the 500 µl of sonicated suspension and incubated on ice for 5 min. The suspension was centrifuged at 10,000 × g for 10 min at 4 °C, and the pellets were discarded. The supernatant was added to 100 µl of washed glutathione-Sepharose beads and incubated for 30 min at 4 °C with inversion. Extracts from transfected COS-7 cells were prepared from a six-well plate 24-48 h post-transfection. Cells were briefly washed in PBS and then 500 µl of lysis buffer (20 mM Tris-HCl, 250 mM NaCl, 3 mM EDTA, 3 mM EGTA, pH 7.6) containing 1% Triton X-100 and protease inhibitors (1:100 dilution, Sigma protease inhibitor mixture containing AEBSF, aprotinin, bestatin, leupeptin, pepstatin A) was added to each well and incubated on ice for 30 min. The resulting extract was cleared of insoluble debris by centrifugation at 10,000 × g for 15 min at 4 °C. 100 µl of Sepharose beads containing the GST fusion proteins were added to 500 µl of the soluble fraction of the lysate and incubated for 1-2 h at 4 °C with gentle inversion. The protein-coupled beads were pelleted by gentle centrifugation and washed five times in PBS. The beads were resuspended in 2× loading buffer, and samples were separated by SDS-polyacrylamide gel electrophoresis with 10% acrylamide gels, transferred to nitrocellulose membrane, and analyzed by immunoblotting as described above.

Coimmunoprecipitation-- COS-7 cells were plated onto six-well plates and transiently transfected with cDNA encoding AKAP79 and HA-tagged Kir2.1. Cell lysates were prepared and cleared as described for GST pull-down assays. 5 µg of rabbit polyclonal HA-probe (Y-11) or 5 µg of rabbit non-immune control serum (Santa Cruz Biotechnologies) was added to 500 µl of cleared lysate and incubated at 4 °C overnight. 30 µl of prewashed protein A-agarose beads (Santa Cruz Biotechnologies) were added to the antibody/lysate mix and incubated with gentle inversion for 90 min at 4 °C. The protein-coupled agarose beads were then pelleted by gentle centrifugation and washed five times in PBS. Immunoprecipitated proteins were recovered in 2× loading buffer, resolved by 10% SDS-polyacrylamide gel electrophoresis, and analyzed by immunoblotting.

Electrophysiology-- Whole-cell currents were recorded from either CHO or COS-7 cells typically 24-48 h post-transfection using an Axopatch 200A amplifier (Axon Instruments). Currents recorded in response to voltage steps were filtered at 5 kHz (-3dB, 8-pole Bessel), digitized at 10 kHz using a DigiData 1200 interface (Axon Instruments), and analyzed using software written in AxoBasic (Axon Instruments) by Dr. N. W. Davies (University of Leicester, UK). Electrodes were pulled from borosilicate glass (outer diameter 1.5 mm; Clarke Electromedical, Pangbourne, UK) and fire polished to give a final resistance of 5 megohm when filled. The pipette-filling solution contained (mM): KCl, 140; MgCl2, 1; EGTA, 10; HEPES, 10; Na2ATP, 3; pH 7.2. The external solution contained (mM): KCl, 35; NaCl, 105; MgCl2, 2, CaCl2, 2; HEPES; 10; pH 7.25. 100 µM cAMP (CalBiochem) was added to the pipette-filling solution in some experiments. The phosphatase inhibitors, okadaic acid and cypermethrin were purchased from Tocris Cookson, Inc. Didecanoyl-rac-glycerol, a cell permeant activator of PKC was purchased from CalBiochem. Phorbol 12-myristate 13-acetate was from Sigma-Aldrich. The junction potential between pipette and external solutions was sufficiently small (<1.5 mV) to be neglected. As far as possible, analogue means were used to correct capacity transients. Up to 90% compensation was routinely used to correct for series resistance. All experiments were performed at room temperature (18-22 °C), and the results are expressed as mean ± S.E. Statistical significance was evaluated using the Student's unpaired t test.

Immunocytochemistry-- HEK-293 or COS-7 cells were plated onto polylysine-coated coverslips and transiently transfected with HA-tagged Kir2.1 and AKAP79. Cells were fixed and permeabilized 48 h post-transfection in a solution containing 80 mM Na2HPO4, 20 mM NaH2PO4, 2% paraformaldehyde, and 0.1% Triton X-100. Fixed cells were incubated overnight at 4 °C with rabbit polyclonal anti-HA and mouse monoclonal anti-AKAP79. Both primary antibodies were diluted 250-fold in PBS with 10% (v/v) goat serum. The following morning, the coverslips were washed 5× 10 min in PBS, then incubated in goat anti-rabbit secondary antibody (cross-adsorbed against mouse) conjugated with Texas Red and goat anti-mouse secondary antibody (cross-adsorbed against rabbit) conjugated with FITC in PBS + 10% goat serum for 2 h at room temperature. Coverslips were washed in PBS for 3× 10 min and mounted onto microscope slides using fluorescent mounting medium (Dako Ltd) before viewing. Confocal images were obtained using a PerkinElmer UltraViewTM imaging system.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Coexpression of AKAP79 and Kir2.1 Has No Effect upon Channel Function-- Membrane currents were recorded from CHO or COS-7 cells using the conventional whole-cell clamp technique typically 24-48 h after transfection with the cDNAs encoding Kir2.1 and AKAP79, or with Kir2.1 alone. To confirm the presence of AKAP79 within cells during electrophysiological recordings, AKAP79 was subcloned into the bicistronic expression vector pIRES2-EGFP (CLONTECH). This permits AKAP79 and EGFP to be translated simultaneously from the same mRNA transcript and allows visual selection of successfully transfected cells expressing AKAP79. The presence of Kir2.1 was confirmed by recording whole-cell Kir currents. For cells expressing Kir2.1 alone, we cotransfected the cDNA encoding Kir2.1 with the empty (no AKAP79) pIRES2-EGFP expression vector. Fig. 1A shows whole-cell currents recorded from a CHO cell transfected with both Kir2.1 and AKAP79. Currents were recorded in response to voltage steps from a holding potential of -35mV (the K+ equilibrium potential, EK) to test potentials ranging from +55 mV and -105 mV in 10 mV increments. Voltage steps positive to EK elicited only small outward currents, whereas steps negative to EK produced substantial inward currents. No significant whole-cell currents were detected in non-transfected cells. The presence of the kinase-anchoring protein, AKAP79 within the cells had no significant effect upon whole-cell Kir2.1 current amplitudes (Fig. 1B) or voltage-dependent properties of Kir channel currents, such as the relationship between whole-cell conductance and voltage (Fig. 1C), or the time constant of Kir2.1 channel gating (Fig. 1D). This suggests that basal Kir2.1 channel activity is unaffected by coexpression with AKAP79.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Characterization of Kir2.1 currents in the presence of AKAP79. A, membrane currents recorded from a single CHO cell expressing AKAP79 and Kir2.1 in response to voltage steps from a holding potential of -35 mV to test potentials ranging from +55 to -105 mV in 10 mV increments. Extracellular [K+] was 35 mM; intracellular [K+] was 140 mM. Outward currents are defined as being positive and are shown as upward deflections; inward currents are defined as being negative. B, mean current-voltage relation for cells expressing AKAP79 and Kir2.1 (filled symbols), or Kir2.1 alone (open circles), n = 6 each. C, relationship between chord conductance and membrane potential for cells expressing AKAP79 and Kir2.1 (filled symbols), or Kir2.1 alone (open symbols). Chord conductance was computed as gK = IK/(V - EK). Its relation to membrane potential may be fitted by a Boltzmann relation with the relative conductance g'K = (1 + exp((V - V0.5)/k))-1, where V0.5 (mV) gives the voltage at which g'K = 0.5 and k (mV) is a factor affecting the steepness of the relationship. For cells expressing AKAP79 and Kir2.1, V0.5 = -32.9 ± 0.9 mV; k = 9.4 ± 1.0 mV (n = 6). For cells expressing Kir2.1 alone, V0.5 = -33.1 ± 1.1 mV; k = 10.6 ± 0.6 mV (n = 6). D, relationship between time constant (t) for activation of inward current and membrane potential for cells expressing AKAP79 and Kir2.1 (filled symbols; n = 6) and cells expressing Kir2.1 alone (open symbols; n = 6). The solid line shows the least-squares fit for cells expressing AKAP79 and Kir2.1, giving t = 3.9 exp(V/32.3) ms. The best fit to the results for Kir2.1 alone (dotted line) gave t = 8.1exp(V/24.1) ms.

AKAP79 Enhances the Response of the Kir2.1 to cAMP but Only in the Presence of Phosphatase Inhibitors-- Preliminary results indicated that elevation of intracellular cAMP had little effect upon whole-cell Kir2.1 currents either in the presence or the absence of AKAP79 (Fig. 2, A and B). In these experiments, whole-cell currents recorded at -80 mV from cells expressing AKAP79 and Kir2.1 increased by only 13.4 ± 1.9% (mean ± S.E.; n = 6) during a 5-min exposure to 100 µM intracellular cAMP. Cells expressing the channel alone showed a similar 11.1 ± 2.8% (n = 6) increase in whole-cell current over the same time interval. It has previously been reported that cAMP-dependent phosphorylation of L-type Ca2+ channel subunits in HEK-293 can only be detected in the presence of phosphatase inhibitors (10). We therefore tested whether the phosphatase inhibitors okadaic acid (an inhibitor of protein phosphatases 1 and 2A) and cypermethrin (a potent inhibitor of calcineurin, phosphatase 2B) augmented the effect of cAMP on Kir2.1 currents. Following a 30-40-min pretreatment of the cells in 200 nM okadaic acid and 200 nM cypermethrin, CHO cells expressing both AKAP79 and Kir2.1 showed a 25.6 ± 3.6% (n = 5) increase in whole-cell Kir2.1 current over a 5-min period when exposed to 100 µM intracellular cAMP (Fig. 2, C and D). In contrast, cells transfected with Kir2.1 alone showed an 8.1 ± 2.5% (n = 5) increase in Kir2.1 current when exposed to 100 µM cAMP over the same period.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2.   The presence of AKAP79 enhanced the response of Kir2.1 to elevated intracellular cAMP but only in the presence of phosphatase inhibitors. A, relative increase in whole-cell current recorded at -80 mV ([K]o = 35 mM; [K]i = 140 mM) over time for cells expressing AKAP79 and Kir2.1 (filled symbols) or Kir2.1 alone (open symbols). 100 µM cAMP was included in the pipette-filling solution. Time = 0 represents the point just after the whole-cell recording configuration has been established. CHO cells expressing both AKAP79 and Kir2.1 showed a 13.4 ± 1.9% (mean ± S.E., n = 6) increase in whole-cell current over a 5-min period, not significantly different from the increase in current seen in cells transfected with Kir2.1 alone, 11.1 ± 2.8% (n = 6) over the same time period (p = 0.42). B, histogram summarizing the percentage increase in whole-cell current recorded at -80 mV after a 5-min period with 100 µM cAMP included in the pipette-filling solution. C, relative increase in whole-cell currents recorded at -80 mV for cells pretreated for 30-40 min in 200 nM okadaic acid and 200 nM cypermethrin before recording. 100 µM cAMP, 200 nM okadaic acid, and 200 nM cypermethrin were included in pipette-filling solution. Cells expressing both AKAP79 and Kir2.1 show a 25.1 ± 3.9% increase in whole-cell current over a 5-min period (n = 5; filled symbols and histogram D), significantly greater than the 8.1 ± 2.5% increase seen in cells expressing Kir2.1 alone (open symbols; n = 5; p < 0.05). D, histogram summarizing the percentage increase in whole-cell currents recorded at -80 mV after a 5-min period for cells pretreated with okadaic acid and cypermethrin.

In the presence of phosphatase inhibitors and AKAP79, the increase in whole-cell Kir current in response to elevated intracellular cAMP was reflected in a 10 mV rightward shift in the relationship between chord conductance and voltage (Fig. 3). The voltage at which the chord conductance was half-maximal (V0.5) shifted from V0.5 = -35.1 ± 1.0 mV in control to V0.5 = -25.0 ± 0.8 mV in cAMP-exposed cells expressing AKAP79 and Kir2.1 (Fig. 3D). The conductance-voltage relation of cells expressing Kir2.1 alone shifted from V0.5 = -34.3 ± 1.0 mV in control to V0.5 = -29.0 ± 1.2 mV in cAMP-exposed cells (Fig. 3B).


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 3.   cAMP induced a rightward shift in the conductance-voltage curve for Kir2.1 in the presence of AKAP79 and phosphatase inhibitors. A, whole-cell currents recorded in the presence of phosphatase inhibitors from a single CHO cell expressing Kir2.1 alone in response to a voltage step from the holding potential of -35 mV to a test potential of -80 mV under control conditions (immediately following patch break-in) and after 10-min exposure to 100 µM intracellular cAMP. B, mean conductance-voltage relationship for 5 cells expressing Kir2.1 alone under control (filled symbols) and following exposure to 100 µM intracellular cAMP for 10 min (open symbols). The voltage at which the conductance was half-maximal shifted from V0.5 = -34.3 ± 1.0 mV in control to V0.5 = -29.0 ± 1.2 mV in cAMP-exposed cells (p < 0.05). C, whole-cell currents recorded in the presence of phosphatase inhibitors from a single CHO cell expressing AKAP79 and Kir2.1 in response to a voltage step from the holding potential of -35 mV to -80 mV under control conditions and after 10-min exposure to 100 µM intracellular cAMP. D, mean conductance-voltage relationship for 5 cells expressing AKAP79 and Kir2.1 under control (filled symbols) and following exposure to 100 µM intracellular cAMP for 10 min (open symbols). The voltage at which the conductance was half-maximal shifted from V0.5 = -35.1 ± 1.0 mV in control to V0.5 = -25.0 ± 0.8 mV in cAMP-exposed cells (p < 0.005)

AKAP79 is a multivalent-anchoring protein that also binds protein kinase C (27, 28). We therefore tested the effect of activators of PKC on Kir2.1 currents in the presence and absence of AKAP79. The extracellular application of 1 µM didecanoyl-rac-glycerol, a cell permeant activator of PKC, or 1 µM phorbol myristate acetate had no effect upon Kir2.1 current in either the presence or absence of AKAP79 or phosphatase inhibitors (not shown).

AKAP79 Coimmunoprecipitates with HA-tagged Kir2.1-- The results of the functional studies outlined above indicate that AKAP79 facilitates cAMP-induced modulation of Kir2.1, presumably by anchoring PKA in close proximity to the ion channel. To establish whether any physical interaction between Kir2.1 and AKAP79 occurs within intact cells, coimmunoprecipitation experiments were performed. COS-7 cells were transfected with cDNAs encoding AKAP79 and HA-tagged Kir2.1. HA-tagged Kir2.1 channels were found to be functionally indistinguishable from untagged wild-type Kir2.1 channels (data not shown). Antibodies directed against the HA epitope tag on Kir2.1 were able to immunoprecipitate AKAP79 (Fig. 4), suggesting that Kir2.1 and AKAP79 exist in a complex within cells.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 4.   AKAP79 coimmunoprecipitates with Kir2.1. COS-7 cells were transfected with cDNAs encoding AKAP79 and HA-tagged Kir2.1. Immunoprecipitation was performed using antibodies directed against the HA epitope tag on Kir2.1 or non-immune IgG as described under "Experimental Procedures." Precipitated proteins were separated by SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose membrane, and immunoblotted with anti-AKAP79. 10% of cell lysate was run in the extract lane. AKAP79 runs as a single band with a molecular size of 79 kDa. Additional bands visible in the extract lane represent unidentified, endogenous COS-7 proteins.

AKAP79 Interacts with the Intracellular N and C Domains of Kir2.1-- Kir channels have a relatively simple structure compared with Na+ and Ca2+ channels and members of the voltage-gated K+ (Kv) channel family. Each subunit in the Kir tetramer consists of an intracellular N and C terminus and two membrane-spanning domains (M1 and M2) separated by a short stretch of amino acids (the H5 or P-region) that dips back into the membrane from the extracellular side to form the selectivity filter and channel pore (21, 22). The only intracellular portions of the channel subunit are found at the N terminus (residues 1-71) before the channel protein disappears into the membrane to form M1, and at the C terminus when the protein emerges from M2 (182). It is therefore relatively straightforward to create GST fusion proteins of the intracellular portions of the Kir channel and test for direct interaction with AKAP79 in pull-down assays.

To identify possible interactions, GST fusion proteins of the intracellular N (residues 1-71) and C (302) terminal domains of Kir2.1 were screened for their ability to bind AKAP79 from lysates of COS-7 cells transfected with cDNA encoding AKAP79. GST fusion proteins of both the N- and the C-domains of Kir2.1 were able to isolate AKAP79 from COS-7 lysates, whereas GST alone failed to interact with AKAP79 (Fig. 5A).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 5.   AKAP79 binds to the N and C regions of Kir2.1. A, GST fusion proteins of the intracellular N (residues 1-71) and C (residues 302-428) domains of Kir2.1 were screened for their ability to isolate AKAP79 from lysates of COS-7 cells transfected with cDNA encoding AKAP79. GST fusion proteins bound to glutathione-Sepharose beads were incubated with cell lysates. Bound proteins were resolved by SDS-polyacrylamide gel electrophoresis, transferred onto nitrocellulose, and immunoblotted with anti-AKAP79. AKAP79 was specifically retained by GST·N-(1-71) and GST·C-(302-428) but not control GST. 10% of the cell lysate was run in the input lane. Membranes were stained for protein to ensure that equivalent amounts of each GST fusion protein were used in each pull-down assay. B, GST fusion proteins of the final eight C-terminal amino acids of Kir2.1 GST·C-(421-428) failed to retain AKAP79.

It has recently been reported that AKAP79 binds to the Src homology 3 (SH3) and guanylate kinase-like (GK) domains of the PDZ protein, PSD-95/SAP90 (31). The C terminus of Kir2.1 contains the conserved PDZ-domain recognition motif (X(S/T)X(V/I)) that mediates binding to members of the PSD-95/SAP90 protein family. Whereas PSD-95 is not present in either COS-7 cells or Escherichia coli, where the GST fusion proteins were originally expressed (see "Experimental Procedures"), we felt it important to test whether AKAP79 binds to Kir2.1 via interaction with an unidentified, endogenous PDZ protein from these cells. For this purpose we constructed a shortened C-terminal GST fusion protein encoding just the last eight C-terminal amino acids of Kir2.1 (421). This shortened GST·C fusion protein, GST·C-(421-428), which includes the Kir2.1 PDZ binding motif, failed to isolate AKAP79, suggesting that AKAP79 binds directly to the intracellular C-domain of Kir2.1 at some point(s) between residues 302 and 421 and not via a C-terminal PDZ protein (Fig. 5B).

AKAP79 and Kir2.1 Are Both Localized to the Plasma Membrane of HEK-293 Cells-- Fig. 6 (A and B) shows confocal images of HEK-293 cells that have been transfected with HA·Kir2.1 and AKAP79, stained with antibodies against the HA epitope tag and AKAP79, and visualized with secondary antibodies conjugated with the non-overlapping fluoroprobes, FITC (Fig. 6A) and Texas Red (Fig. 6B), respectively. The images show both proteins to be localized to the plasma membrane, demonstrating proximity between Kir2.1 and AKAP79 within intact cells. Interestingly, we were unable to use EGFP-tagged Kir2.1 channels to monitor Kir2.1 distribution, as the presence of AKAP79 seemed to quench the EGFP·Kir2.1 fluorescence. Fig. 6 (C and D) show typical confocal images of a HEK-293 cell transfected with EGFP-tagged Kir2.1 (EGFP attached to the N terminus of Kir2.1) and AKAP79. The cell has been permeabilized and stained with anti-AKAP79. EGFP fluorescence is almost undetectable (Fig. 6C). AKAP79 distribution within the same cell is shown in Fig. 6D. The reduction in EGFP fluorescence is not a result of cell permeabilization because permeabilized HEK-293 cells expressing EGFP·Kir2.1 alone retain their brightness (Fig. 6E). Nor is the fluorescence reduction simply because of the coexpression of AKAP79 and EGFP, because cells transfected with EGFP and AKAP79 were indistinguishable from cells transfected with EGFP alone (data not shown). Rather, the effect of reduced fluorescence seems to be a side effect of the association of Kir2.1 and AKAP79. EGFP fluorescence is known to be sensitive to a number of factors, particularly pH, and it seems possible that the anchoring of AKAP79 and its associated proteins may change some factor in the very local environment of the ion channel that affects the fluorescence of the attached EGFP molecule.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 6.   AKAP79 and Kir2.1 are localized to the plasma membrane. A and B, confocal image of HEK-293 cells transfected with AKAP79 and HA·Kir2.1 and stained with anti-AKAP79 and anti-HA. The subcellular distribution of HA·Kir2.1 (A) was visualized by addition of a FITC-conjugated secondary antibody, and AKAP79 by a Texas Red-conjugated secondary antibody (B). Both proteins are found predominantly at the plasma membrane. C and D, confocal image of HEK-293 cells transfected with EGFP·Kir2.1 and AKAP79. Cells have been permeabilized and stained with anti-AKAP79. EGFP·Kir2.1 fluorescence (C) is greatly reduced by coexpression with AKAP79, when compared with EGFP·Kir2.1 alone (E).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Our findings suggest that the protein kinase A-anchoring protein, AKAP79, associates directly with intracellular regions of the strong inwardly rectifying K+ channel, Kir2.1 to anchor PKA close to channel phosphorylation sites. The primary sequence of Kir2.1 suggests the presence of one putative PKA phosphorylation site at position Ser-426 on the C terminus and four putative PKC phosphorylation sites, two on the N terminus (Ser-3, Thr-6) and two on the C terminus (Ser-357, Thr-383). AKAP79, in common with many adaptor proteins, binds several different enzymes, in this case PKA, PKC and the Ca2+ calmodulin-dependent protein phosphatase-2B, calcineurin (27, 28). Whereas activators of PKC had no discernable effect upon Kir2.1 currents either in the presence or in the absence of AKAP79, elevation of intracellular cAMP caused a marked increase in whole-cell Kir2.1 current in the presence but not in the absence of AKAP79. Interestingly, the effects of elevated cAMP were only observed in cells pretreated with the phosphatase inhibitors okadaic acid and cypermethrin. Phosphatase anchoring via association with AKAP79 could potentially increase phosphatase activity close to the channel, although cypermethrin, which specifically inhibits calcineurin with an IC50 in the subnanomolar range, was found to be largely ineffective on its own (data not shown). Alternatively, the reliance on phosphatase inhibitors may simply reflect a relatively high endogenous phosphatase activity within these cell systems and suggests that channel phosphorylation and dephosphorylation may be a fast, dynamic process. There has been a report of similar findings for cloned L-type Ca2+ channels expressed in HEK-293 cells where phosphorylation of the alpha  1C channel subunit was only observed in the presence of the phosphatase inhibitors, okadaic acid and FK506, both being ineffective on their own (10). This and other studies highlight one of the features of heterologous expression systems, which while offering the advantage of a controlled experimental environment, often do not mimic the native conditions needed for ion channel modulation. For example, the weak inward rectifying K+ channel Kir1.1 (ROMK1) is predominantly expressed in the kidney where it plays an important role in K+ homeostasis (22). The anti-diuretic hormone, vasopressin is known to enhance the activity of native Kir1.1 channels in the kidney via a cAMP-dependent pathway (32, 33). When cloned Kir1.1 channels are expressed in intact Xenopus oocytes, however, the channels appear insensitive to elevation of intracellular cAMP, unless coexpressed with the kinase-anchoring protein, AKAP79 (14). Overlay assays using the AKAP-binding RII subunit of PKA as a probe show the presence of a 100-120 kDa RII-binding protein in kidney membranes, which is absent in oocytes. This suggests that cAMP-induced modulation of Kir1.1 relies upon an anchored pool of PKA, which is not naturally present within oocyte membranes.

The functional effects on channel activity of coexpressing AKAP79 and Kir2.1 suggest that AKAP79 also facilitates the phosphorylation of Kir2.1 by anchoring PKA close to the ion channel. The low molecular weight anchoring protein AKAP15/18 has been shown to target PKA to L-type Ca2+ channels by membrane association through myristoylation and palmitoylation of residues at its N terminus and, possibly, by direct interaction with Ca2+ channel subunits (12, 13). AKAPs contain at least two functional domains: an amphipathic helix that binds the regulatory (RII) subunits of the PKA holoenzyme (5, 6) and a specialized targeting region that tethers the AKAP·PKA complex to specific intracellular sites (7). Early studies suggested that AKAP79 targeting was mediated through interactions with cytoskeletal proteins (34, 35), although more recent studies suggest that AKAP79 is anchored to the plasma membrane through direct binding of basic domains on the protein to acidic phospholipids, including the phosphoinositide PtdIns(4,5)P2 (36). While the primary target of AKAP79 is the plasma membrane, there may be a subsidiary interaction with intracellular regions of channel proteins to create a channel/AKAP complex that could enhance the speed and specificity of PKA-induced phosphorylation. Coimmunoprecipitation of AKAP79 with HA-tagged Kir2.1 certainly suggests that these two proteins exist in a complex within intact cells. Kir channels have a relatively simple structure when compared with Na+/Ca2+ channels, and Kv channels, and this makes it possible to create GST fusion proteins of the entire intracellular portion of the Kir channel and test for direct interaction with AKAP79. GST pull-down assays demonstrate that AKAP79 binds to both the N and C intracellular domains of Kir2.1. Interaction between AKAPs and their target proteins at multiple sites is not unprecedented because AKAP79 has recently been shown to bind to the beta 2-adrenergic receptor through sites on both the third intracellular loop and at the C-terminal tail (37).

AKAP79 also binds to the Src homology 3 (SH3) and guanylate kinase-like (GK) domains of the membrane-associated guanylate kinase (MAGUK) proteins, PSD-95 and SAP97. This recruits PKA to ionotropic glutamate receptors because PSD-95 interacts with NR2B subunits of the NMDA receptor, and SAP97 binds to GluR1 subunits of AMPA receptors (31). The C terminus of Kir2.1 contains the PDZ-domain recognition motif (X(S/T)X(V/I)) that mediates binding to the PSD-95/SAP90 protein family, and Kir2.1 has been shown to interact with PSD-95 in yeast two-hybrid screens and heterologous expression systems (38). The C-terminal AKAP binding we detect for Kir2.1 is unlikely to be via interaction with a PDZ protein because GST·C-(421-428), a shortened C-terminal fusion protein harboring the PDZ motif, failed to isolate AKAP79 in pull-down assays. Nevertheless, the ability of AKAP79 to bind to PSD-95 and directly to intracellular regions of Kir2.1 may offer additional stability to potential protein complexes containing the ion channel, PDZ protein and AKAP. It is also notable that NMDA receptors retain the option of recruiting PKA through the simultaneous association of two separate anchoring proteins: AKAP79, which binds to the receptor via PSD-95 (31) and yotiao, which binds directly to the C-terminal C1 exon cassette of the NMDA receptor (9). Because the native AKAP partner of Kir2.1 has yet to be identified, it is tempting to speculate that a similar situation may exist for K+ channels.

In conclusion, we present evidence for the direct association of a protein kinase A-anchoring protein with a K+ channel. This is potentially important given the unique role of K+ channels in shaping the electrical properties and firing patterns of cells, and the profound effects that K+ channel modulation has upon cellular excitability. It seems increasingly likely that in vivo K+ channels, like Ca2+ channels and ionotropic glutamate receptors, exist in highly organized complexes made up of AKAPs and associated signaling proteins that ensure rapid and efficient phosphorylation of the channel protein in response to localized cell signals.

    FOOTNOTES

* This work was supported by the Royal Society and the Wellcome Trust.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence should be addressed. Tel.: 116 252 3090; Fax: 116 252 5045; E-mail: cd12@le.ac.uk.

Published, JBC Papers in Press, April 3, 2001, DOI 10.1074/jbc.M101425200

2 The HUGO Gene Nomenclature Committee has recently approved a new nomenclature scheme for the AKAP family.

    ABBREVIATIONS

The abbreviations used are: PKA, cyclic AMP-dependent protein kinase; AKAP, cyclic AMP-dependent protein kinase-anchoring protein; AMPA, alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid; NMDA, N-methyl-D-aspartate; PKC, protein kinase C; C-terminal, carboxyl-terminal; N-terminal, amino-terminal; HA, hemagglutinin; CHO, Chinese hamster ovary; COS-7, African Green monkey kidney cells; HEK-293, human embryonic kidney 293; EGFP, enhanced green fluorescent protein; GST, glutathione S-transferase; AEBSF, 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride; Ptd-Ins(4, 5)P2, phosphatidylinositol 4,5-bisphosphate; ROMK1, renal outer medulla potassium channel; PBS, phosphate-buffered saline; FITC, fluorescein isothiocyanate; Kir, inwardly rectifying potassium channel.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Faux, M. C., and Scott, J. D. (1996) Trends Biochem. Sci. 21, 312-315[CrossRef][Medline] [Order article via Infotrieve]
2. Pawson, T., and Scott, J. D. (1997) Science 278, 2075-2080[Abstract/Free Full Text]
3. Rubin, C. S. (1994) Biochim. Biophys. Acta 1224, 467-479[Medline] [Order article via Infotrieve]
4. Dell'Acqua, M. L., and Scott, J. D. (1997) J. Biol. Chem. 272, 12881-12884[Free Full Text]
5. Carr, D. W., Stofko-Hahn, R. E., Fraser, I. D. C., Bishop, S. M., Acott, T. S., Brennen, R. G., and Scott, J. D. (1991) J. Biol. Chem. 266, 14188-14192[Abstract/Free Full Text]
6. Hausken, Z. E., Dell'Acqua, M. L., Coghlan, V. M., and Scott, J. D. (1996) J. Biol. Chem. 271, 29016-29022[Abstract/Free Full Text]
7. Colledge, M., and Scott, J.D (1999) Trends Cell Biol. 9, 216-221[CrossRef][Medline] [Order article via Infotrieve]
8. Rosenmund, C., Carr, D. W., Bergeson, S. E., Nilaver, G., Scott, J. D., and Westbrook, G. L. (1994) Nature 368, 853-856[CrossRef][Medline] [Order article via Infotrieve]
9. Westphal, R. S., Tavalin, S. J., Lin, J. W., Alto, N. M., Fraser, I. D. C., Langeberg, L. K., Sheng, M., and Scott, J. D. (1999) Science 285, 93-96[Abstract/Free Full Text]
10. Gao, T., Yatani, A., Dell'Acqua, M. L., Sako, H., Green, S. A., Dascal, N., Scott, J. D., and Hosey, M. M. (1997) Neuron 19, 185-196[Medline] [Order article via Infotrieve]
11. Wang, Z. W., and Kotlikoff, M. I. (1996) Am. J. Physiol. 15, L100-L105
12. Gray, P. C., Johnson, B. D., Westenbroek, R. E., Hays, L. G., Yates, J. R., Scheuer, T., Catterall, W. A., and Murphy, B. J. (1998) Neuron. 20, 1017-1026[Medline] [Order article via Infotrieve]
13. Fraser, I. D. C., Tavalin, S. J., Lester, L. B., Langeberg, L. K., Westphal, A. M., Dean, R. A., Marrion, N. V., and Scott, J. D. (1998) EMBO J. 17, 2261-2272[Abstract/Free Full Text]
14. Ali, S., Chen, X., Lu, M., Xu, J. Z., Lerea, K. M., Hebert, S. C., and Wang, W. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 10274-10278[Abstract/Free Full Text]
15. Matsuda, H., Saigusa, A., and Irisawa, H. (1987) Nature 325, 156-158[CrossRef][Medline] [Order article via Infotrieve]
16. Lopatin, A. N., Makhina, E. N., and Nichols, C. G. (1994) Nature 372, 366-369[CrossRef][Medline] [Order article via Infotrieve]
17. Hille, B. (1992) Ionic Channels of Excitable Membranes , 2nd Ed. , pp. 127-130, Sinauer Associates, Sunderland, MA
18. Doupnik, C. A., Davidson, N., and Lester, H. A. (1995) Curr. Opin. Neurobiol. 5, 268-277[CrossRef][Medline] [Order article via Infotrieve]
19. Karschin, A. (1999) News Physiol. Sci. 14, 215-220[Abstract/Free Full Text]
20. Ruppersberg, J. P. (2000) Pflug. Arch. 441, 1-11[CrossRef][Medline] [Order article via Infotrieve]
21. Kubo, Y., Baldwin, T. J., Jan, Y. N., and Jan, L. Y. (1993) Nature 362, 127-133[CrossRef][Medline] [Order article via Infotrieve]
22. Ho, K., Nichols, C. G., Lederer, W. J., Lytton, J., Vassilev, P. M., Kanazirska, M. V., and Hebert, S. C. (1993) Nature 362, 31-38[CrossRef][Medline] [Order article via Infotrieve]
23. Dascal, N., Schreibmayer, W., Lim, N. F., Wang, W., Chavkin, C., DiMagno, L., Labarca, C., Kieffer, B. L., Gaveriaux-Ruff, C., Trollinger, D., Lester, H. A., and Davidson, N. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10235-10239[Abstract]
24. Fakler, B., Brandle, U., Glowatzki, E., Zenner, H. P., and Ruppersberg, J. P. (1994) Neuron 13, 1413-1420[Medline] [Order article via Infotrieve]
25. Henry, P., Pearson, W. L., and Nichols, C. G. (1996) J. Physiol. (Lond.) 495, 681-688[Abstract]
26. Wischmeyer, E., and Karschin, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5819-5823[Abstract/Free Full Text]
27. Coghlan, V. M., Perrino, B. A., Howard, M., Langeberg, L. K., Hicks, J. B., Gallatin, W. M., and Scott, J. D. (1995) Science 267, 108-112[Medline] [Order article via Infotrieve]
28. Klauck, T. M., Faux, M. C., Labudda, K., Langeberg, L. K., Jaken, S., and Scott, J. D. (1996) Science 271, 1589-1592[Abstract]
29. Dart, C., Leyland, M. L., Barrett-Jolley, R., Shelton, P. A., Spencer, P. J., Conley, E. C., Sutcliffe, M. J., and Stanfield, P. R. (1998) J. Physiol (Lond.) 511.1, 15-24[Abstract/Free Full Text]
30. Leyland, M. L., Dart, C., Spencer, P. J., Sutcliffe, M. J., and Stanfield, P. R. (1999) Pflug. Arch. 438, 778-781[CrossRef][Medline] [Order article via Infotrieve]
31. Colledge, M., Dean, R. A, Scott, G. K., Langeberg, L. K., Huganir, R. L., and Scott, J.D (2000) Neuron 27, 107-119[Medline] [Order article via Infotrieve]
32. Cassola, A. C., Giebisch, G., and Wang, W. (1993) Am. J. Physiol. 264, F502-F509[Abstract/Free Full Text]
33. Wang, W. H. (1994) Am. J. Physiol. 267, F599-F605[Abstract/Free Full Text]
34. Glantz, S. B., Li, Y., and Rubin, C. S. (1993) J. Biol. Chem. 268, 12796-12804[Abstract/Free Full Text]
35. Li, Y., Ndubuka, C., and Rubin, C. S. (1996) J. Biol. Chem. 271, 16862-16869[Abstract/Free Full Text]
36. Dell'Acqua, M. L., Faux, M. C., Thorburn, J., Thorburn, A., and Scott, J. D. (1998) EMBO J. 17, 2246-2260[Abstract/Free Full Text]
37. Fraser, I. D. C., Cong, M., Kim, J., Rollins, E. N., Daaka, Y., Lefkowitz, R. J., and Scott, J. D. (2000) Curr. Biol. 10, 409-412[CrossRef][Medline] [Order article via Infotrieve]
38. Nehring, R. B., Wischmeyer, E., Döring, F., Veh, R. W., Sheng, M., and Karschin, A. (2000) J. Neurosci. 20, 156-162[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.